Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus LUXIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus LUXIQ.
COR-OTICIN vs LUXIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
1-2 drops in each affected ear twice daily for 7 days.
Topical: Apply a thin film to affected areas of the scalp twice daily (morning and evening) for 2 weeks; do not exceed 50 g per week.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal half-life: 3-5 hours; in renal impairment may extend to 8 hours.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal: 30% unchanged; biliary/fecal: 70% as metabolites.
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid